NASDAQ:PRFX PainReform Q4 2025 Earnings Report $0.95 0.00 (0.00%) Closing price 10/1/2026 03:59 PM EasternExtended Trading$0.97 +0.02 (+1.76%) As of 10/1/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast PainReform EPS ResultsActual EPS-$0.99Consensus EPS -$612.00Beat/MissBeat by +$611.02One Year Ago EPSN/APainReform Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APainReform Announcement DetailsQuarterQ4 2025Date4/6/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile PainReform Earnings HeadlinesPRF Technologies' GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power OptimizationSeptember 16, 2026 | globenewswire.comPRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading PlatformSeptember 9, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy BusinessSeptember 3, 2026 | globenewswire.comPRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy PlatformsJuly 27, 2026 | globenewswire.comPRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026July 21, 2026 | globenewswire.comSee More PainReform Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email. Email Address About PainReformPainReform (NASDAQ:PRFX) (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing therapies for the management of acute postoperative pain. The company’s approach is designed to provide prolonged local pain relief while potentially reducing reliance on opioid medications after surgery. PainReform’s lead product candidate, PRF-110, is an investigational extended-release formulation of ropivacaine, a local anesthetic. The product is designed to be administered at the surgical site and gradually release the anesthetic over an extended period, with the goal of providing sustained pain control during the early recovery period following surgery. Founded in Israel, PainReform has pursued the clinical development of its product candidates for potential use in postoperative pain management markets, including the United States and other international markets. PRF-110 remains subject to clinical evaluation and regulatory review, and its availability and commercial use depend on receiving applicable approvals.View PainReform ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
